14 slides from Insight Molecular Diagnostics's earnings presentation, Mar 10, 2022
Slide 1: Q4 2021 Financial Results & Operating Highlights
Q42021 Financial Results & Operating Highlights March 10, 2022
Slide 2: Forward Looking Statements
Forward Looking Statements Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” “may,” and similar expressions) are forward-looking statements. These statements include, am
Slide 3: Our Mission
Our Mission Oncocyte is a precision diagnostics company with a mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey. 3
Slide 4: The Emerging Patient Management Paradigm
The Emerging Patient Management Paradigm Transforming a deadly disease to a chronic disorder Adjuvant Therapy Selection Targeted/ Immunotherapy Resistance – Selection Targeting – Disease Burden Therapeutic – Response Monitoring – – Minimal Residual Molecular Disease Remission – BASELINE – TIME PROGR
Slide 5: Oncocyte's Determa Platform Strategy
Oncocyte’s Determ a Platform Strategy Products Deliver Critical I nform ation Throughout the Patient Journey I m proving Outcom es and Reducing Costs Treatment Decision Patient Monitoring Should I give Should I give Should I give Is the therapy Is the cancer adjuvant chemo? targeted therapy? immunot
Slide 6: Oncocyte 2022 Success Milestones
Oncocyte 2022 Success Milestones Market-focused initiatives to support clinical utility and oncologist adoption • Full market launch of DetermaIO/Tx • IO submission to CMS • Registry execution • Continue IO clinical studies • Sales execution • Close agreement with global platform Co. • Add strategic
Slide 7: DetermaRX Q4 – 2021 YE Highlights
DetermaRX Q4 – 2021 YE Highlights Should I give adjuvant chemo? • Completed Tech Transfer to Burning Rock • Quarter over quarter US testing volumes grew Treatment 54% and revenues grew 104% vs Q3 Stratification • Samples volume grew 106% and Revenue grew 152% in Q42021 vs Q42020 • Ended 2021 with to
Slide 8: DetermaIO Q4 - 2021 YE Highlights
DetermaIO Q4 - 2021 YE Highlights Should I give immunotherapy? • Launched 7 early adopter sites via Early Access Program and established KOL Speaker Program Treatment • First Randomized, Prospective Trial presented at Selection ESMO • Predictive data in TNBC presented at SABCS • Presented data on ov
Slide 9: DetermaTx Q4 - 2021 YE Highlights
DetermaTx Q4 - 2021 YE Highlights Should I give targeted therapy? • Completed In Silico design, received 1st custom panel in Q4 Targeted Therapy • Initiated Clinical Validation Selection • On track to complete clinical validation in late Q2 • 2H CMS Submission planned under existing Clinical Launch
Slide 10: DetermaCNI Q4 - 2021 YE Highlights
DetermaCNI Q4 - 2021 YE Highlights • Blood-only test for monitoring Patient Monitoring • Patented genome wide assessment offers Is the therapy working? advantages current MRD testing methods • 5 publications to date – over 500 patients studied • 1200+ patients under study in EU across several Therap
Slide 11: Transplant Update
Transplant Update Q4/2021 YE Earnings Call 03/10/22
Slide 12: TheraSure Update
TheraSure Update • Received dPCR patent for dd cfDNA Monitoring in Transplant and Oncology in Q4’21 • Initiated LDT Tech Transfer from GmbH to Nashville in Q4’21 • On track for completion of LDT validation by end of Q1 • CMS Pre-meeting complete (early Dec 2021) • Analytical validation and CMS Dossi
Slide 13: OCX 2021 Results
OCX 2021 Results ONCOCYTE
Slide 14: Investor Contact
Investor Contact: Mitch Levine Chief Financial Officer IR@oncocyte.com IR 0507 0920